Cargando…

Inflammatory Burden and Immunomodulative Therapeutics of Cardiovascular Diseases

Phenotyping cardiovascular illness and recognising heterogeneities within are pivotal in the contemporary era. Besides traditional risk factors, accumulated evidence suggested that a high inflammatory burden has emerged as a key characteristic modulating both the pathogenesis and progression of card...

Descripción completa

Detalles Bibliográficos
Autores principales: Kao, Ting-Wei, Huang, Chin-Chou
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8775955/
https://www.ncbi.nlm.nih.gov/pubmed/35054989
http://dx.doi.org/10.3390/ijms23020804
_version_ 1784636713353609216
author Kao, Ting-Wei
Huang, Chin-Chou
author_facet Kao, Ting-Wei
Huang, Chin-Chou
author_sort Kao, Ting-Wei
collection PubMed
description Phenotyping cardiovascular illness and recognising heterogeneities within are pivotal in the contemporary era. Besides traditional risk factors, accumulated evidence suggested that a high inflammatory burden has emerged as a key characteristic modulating both the pathogenesis and progression of cardiovascular diseases, inclusive of atherosclerosis and myocardial infarction. To mechanistically elucidate the correlation, signalling pathways downstream to Toll-like receptors, nucleotide oligomerisation domain-like receptors, interleukins, tumour necrosis factor, and corresponding cytokines were raised as central mechanisms exerting the effect of inflammation. Other remarkable adjuvant factors include oxidative stress and secondary ferroptosis. These molecular discoveries have propelled pharmaceutical advancements. Statin was suggested to confer cardiovascular benefits not only by lowering cholesterol levels but also by attenuating inflammation. Colchicine was repurposed as an immunomodulator co-administered with coronary intervention. Novel interleukin-1β and −6 antagonists exhibited promising cardiac benefits in the recent trials as well. Moreover, manipulation of gut microbiota and associated metabolites was addressed to antagonise inflammation-related cardiovascular pathophysiology. The gut-cardio-renal axis was therein established to explain the mutual interrelationship. As for future perspectives, artificial intelligence in conjunction with machine learning could better elucidate the sequencing of the microbiome and data mining. Comprehensively understanding the interplay between the gut microbiome and its cardiovascular impact will help identify future therapeutic targets, affording holistic care for patients with cardiovascular diseases.
format Online
Article
Text
id pubmed-8775955
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-87759552022-01-21 Inflammatory Burden and Immunomodulative Therapeutics of Cardiovascular Diseases Kao, Ting-Wei Huang, Chin-Chou Int J Mol Sci Review Phenotyping cardiovascular illness and recognising heterogeneities within are pivotal in the contemporary era. Besides traditional risk factors, accumulated evidence suggested that a high inflammatory burden has emerged as a key characteristic modulating both the pathogenesis and progression of cardiovascular diseases, inclusive of atherosclerosis and myocardial infarction. To mechanistically elucidate the correlation, signalling pathways downstream to Toll-like receptors, nucleotide oligomerisation domain-like receptors, interleukins, tumour necrosis factor, and corresponding cytokines were raised as central mechanisms exerting the effect of inflammation. Other remarkable adjuvant factors include oxidative stress and secondary ferroptosis. These molecular discoveries have propelled pharmaceutical advancements. Statin was suggested to confer cardiovascular benefits not only by lowering cholesterol levels but also by attenuating inflammation. Colchicine was repurposed as an immunomodulator co-administered with coronary intervention. Novel interleukin-1β and −6 antagonists exhibited promising cardiac benefits in the recent trials as well. Moreover, manipulation of gut microbiota and associated metabolites was addressed to antagonise inflammation-related cardiovascular pathophysiology. The gut-cardio-renal axis was therein established to explain the mutual interrelationship. As for future perspectives, artificial intelligence in conjunction with machine learning could better elucidate the sequencing of the microbiome and data mining. Comprehensively understanding the interplay between the gut microbiome and its cardiovascular impact will help identify future therapeutic targets, affording holistic care for patients with cardiovascular diseases. MDPI 2022-01-12 /pmc/articles/PMC8775955/ /pubmed/35054989 http://dx.doi.org/10.3390/ijms23020804 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Kao, Ting-Wei
Huang, Chin-Chou
Inflammatory Burden and Immunomodulative Therapeutics of Cardiovascular Diseases
title Inflammatory Burden and Immunomodulative Therapeutics of Cardiovascular Diseases
title_full Inflammatory Burden and Immunomodulative Therapeutics of Cardiovascular Diseases
title_fullStr Inflammatory Burden and Immunomodulative Therapeutics of Cardiovascular Diseases
title_full_unstemmed Inflammatory Burden and Immunomodulative Therapeutics of Cardiovascular Diseases
title_short Inflammatory Burden and Immunomodulative Therapeutics of Cardiovascular Diseases
title_sort inflammatory burden and immunomodulative therapeutics of cardiovascular diseases
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8775955/
https://www.ncbi.nlm.nih.gov/pubmed/35054989
http://dx.doi.org/10.3390/ijms23020804
work_keys_str_mv AT kaotingwei inflammatoryburdenandimmunomodulativetherapeuticsofcardiovasculardiseases
AT huangchinchou inflammatoryburdenandimmunomodulativetherapeuticsofcardiovasculardiseases